All Activity

Many thanks with regard to supplying current improvements concerning the issue, We anticipate study much more. http://king33w.org

Frequent goes to here i will discuss the obvious way to appreciate it on your attempt, which often is why Now i am viewing the internet site day-to-day, in search of completely new, useful facts. Quite a few, many thanks! online gambling in Iowa Certainly great, remarkable, fact-filled tips these. Ones own content articles Be required to fail, thinking that obviously is true these on top of that. One normally generate an intriguing browse. On earth do you enlighten So i'm shocked?: )#) Compete the great articles and reviews. online gambling in Arkansas I had most recently initiated a fabulous web page, the details you will provide you with here comes with really helped others really. Regards just for all of the effort & succeed. online gambling in Quebec Helpful — I valued the transparency on player complaint resolution timelines. Quick, fair resolution processes prevent toxic situations from escalating. Real votes showed which teams are responsive. Slot qris Excellent roundup — I appreciated the filter for low-population but active servers. Smaller communities often offer friendlier vibes and cooperation. Real player rankings showed which small servers thrive. situs susterslot Excellent list — the server comparison tools simplified my decision. Side-by-side stats like drop rates and population were priceless. Real votes added the final confirmation. situs slot Certainly great, remarkable, fact-filled tips these. Ones own content articles Be required to fail, thinking that obviously is true these on top of that. One normally generate an intriguing browse. On earth do you enlighten So i'm shocked?: )#) Compete the great articles and reviews. togel online Frequent goes to here i will discuss the obvious way to appreciate it on your attempt, which often is why Now i am viewing the internet site day-to-day, in search of completely new, useful facts. Quite a few, many thanks! togel online I had most recently initiated a fabulous web page, the details you will provide you with here comes with really helped others really. Regards just for all of the effort & succeed. situs slot

Wow, this post really hits hard, huh? It's like a reality check on what many face behind bars. Makes you wanna spread some love; maybe share this <a href="https://kirkified.ai/" target="_blank">Kirkified</a> for a bit of laughter amidst the chaos!

You make so many great points here that I read your article a couple of times. Your views are in accordance with my own for the most part. This is great content for your readers. link gacor

This site has such a nice collection of free happy birthday cards. Perfect for sending quick digital greetings!

This was a fantastic read. The way you organize and explain complex topics makes it so easy to understand. It’s rare to find content this informative. Please continue posting more helpful information like this! 신용카드현금화

Great to see a program Slope Rider dedicated to empowering women-led cannabis startups—strong boost for innovation and visibility!

A Florida Republican lawmaker has introduced a bill to expand the state’s medical marijuana program in a number of ways, including by allowing doctors to recommend cannabis to any patient who has a condition for which they have been prescribed opioids. The legislation from Rep. Bill Partington (R), filed for the 2026 session on Wednesday, would also make it so medical marijuana registrations could last up to two years instead of the current 30 weeks, and it’d waive patient registration fees for honorably discharged military veterans. Under the proposal, doctors would additionally be able to recommend medical cannabis via telehealth without a physical examination—expanding a current policy that allows renewals, but not initial certifications, to be conducted remotely. There are also reciprocity provisions built into the measure, requiring regulators to create a process to issue medical cannabis registration cards to “nonresidents who are actively enrolled in the medical cannabis program of another jurisdiction recognized by the department within 1 business day.” It specifies that “a visiting qualified patient may engage in all conduct authorized for a qualified patient.” Another section of the bill stipulates that doctors could certify patients to receive up to 10 70-day supply limits of smokable medical marijuana, rather than three. They could also issue up to 20 35-day supply limits instead of the current six. The measure is being filed just days after a Florida Democratic senator introduced legislation for the 2026 session that would legalize home cultivation of marijuana for registered medical cannabis patients in the state. The proposal would permit qualified patients who are at least 21 years old to cultivate up to six flowering plants for personal, therapeutic use. Those patients could also buy seeds and clones from licensed dispensaries. If enacted into law, the bill would become law on July 1, 2026. A similar proposal was introduced at the beginning of this year by Sen. Joe Gruters (R), who is now chairman of the Republican National Committee, but it did not advance. Gruters and Kim Rivers—the CEO of Trulieve, a medical marijuana company that provided the bulk of funding for an unsuccessful cannabis legalization ballot initiative last year—also met with Preident Donald Trump ahead of his endorsement of the constitutional amendment, as well as federal rescheduling and industry banking access. Notably, Amendment 3 would not have legalized home cultivation of marijuana—a detail seized on by some critics of the industry-backed proposal. The campaign behind that initiative, Smart & Safe Florida, recently said it’s collected more than one million signatures to put a new version of the legalization measure on the 2026 ballot—and so it voluntarily declined to appeal a legal case in which a judge allowed state officials to invalidate about 200,000 petitions over a largely procedural issue. Smart & Safe filed a separate lawsuit with the state Supreme Court over another issue last month, alleging that officials are violating election laws by stalling a required review process for the measure without justification. The state has since agreed to move forward with the processing. A federal judge in August separately delivered a win to the campaign—granting “complete relief” from provisions of a law the governor signed to impose other serious restrictions on signature gathering. In March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to Gov. Ron DeSantis (R). The money was used to fight against a citizen ballot initiative, vehemently opposed by the governor, that would have legalized marijuana for adults. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said in February that the newest marijuana legalization measure is in “big time trouble” with the state Supreme Court, predicting it will be blocked from going before voters next year. “There’s a lot of different perspectives on on marijuana,” DeSantis said. “It should not be in our Constitution. If you feel strongly about it, you have elections for the legislature. Go back candidates that you believe will be able to deliver what your vision is on that.” “But when you put these things in the Constitution—and I think, I mean, the way they wrote, there’s all kinds of things going on in here. I think it’s going to have big time trouble getting through the Florida Supreme Court,” he said. The latest initiative was filed with the secretary of state’s office just months after the initial version failed during the November 2024 election—despite an endorsement from President Donald Trump. Smart & Safe Florida is hoping the revised version will succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” Last year, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released in February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In the background, a recent poll from a Trump-affiliated research firm found that nearly 9 in 10 Florida voters say they should have the right to decide to legalize marijuana in the state. Meanwhile, a pro-legalization GOP state lawmaker recently filed a bill to amend state law to codify that the public use of marijuana is prohibited. Rep. Alex Andrade (R), the sponsor, said earlier this year that embracing cannabis reform is a way for the Republican party to secure more votes from young people. Separately, Florida medical marijuana officials are actively revoking the registrations of patients and caregivers with drug-related criminal records. The policy is part of broad budget legislation signed into law earlier this year by DeSantis. The provisions in question direct the state Department of Health (DOH) to cancel registrations of medical marijuana patients and caregivers if they’re convicted of—or plead guilty or no contest to—criminal drug charges. The post Florida GOP Lawmaker Files Medical Marijuana Expansion Bill Allowing Patients To Qualify If They’ve Been Prescribed Opioids appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Democratic senators have introduced a new bill to create a federal regulatory framework for hemp-derived cannabinoids and allow states to set their own rules for products such as CBD. The legislation, shared exclusively with Marijuana Moment ahead of its introduction on Wednesday, is being sponsored by Sens. Ron Wyden (D-OR) and Jeff Merkley (D-OR). It comes at a critical time for the industry, which is facing significant upheaval after President Donald Trump signed a spending bill last month that includes provisions to widely recriminalize consumable cannabinoid products. The senators’ proposal would set THC limits on hemp products, allowing up to 5 milligrams per serving and a maximum of 50 milligrams per container across all types other than beverages. Hemp drinks could have up to 10 milligrams of THC per container. The Food and Drug Administration (FDA) would also be empowered to ensure that certain safety standards are met in the marketplace—including making sure that products aren’t marketed to children. “There’s no question that more needs to be done to protect kids and consumers from unsafe, untested hemp products,” Wyden told Marijuana Moment. “We learned from the failed war on drugs that a one-size-fits all approach that bans hemp products from the market outright does nothing to protect kids and consumers, and will be a gut-punch to thousands of jobs and small businesses across the country,” he said. “My legislation takes the thoughtful and measured approach necessary to implement strong consumer protection regulations while fostering growth and innovation in this growing industry.” Merkley said that “a blanket ban on hemp harms research and the entire industry.” “Instead, the FDA must establish clear, commonsense guidelines—as it does for other foods, drinks, and products—to protect the health of all Americans and prevent children from purchasing these hemp products,” he said. The new bill, the Cannabinoid Safety and Regulation Act, represents something of a compromise between both sides of the hemp policy debate. Rather than impose an outright ban as is currently set to take effect next November, it would establish a regulatory pathway that many stakeholders view as a more sensible alternative that wouldn’t threaten to dramatically undermine the industry. Businesses selling hemp cannabinoid items meant for human consumption would need to register with FDA and comply with the agency’s safety regulations. Such products could not be sold to people under 21, and they would need to adhere to federal labeling requirements. The measure would additionally create a $125 million cannabis use prevention grant program under the U.S. Department of Health and Human Services (HHS), with the intent of preventing underage consumption of intoxicating cannabinoids. The bill specifically preserves the rights of states to set tighter regulations, including banning the products altogether as has played out in certain markets. States that allow the products would need to abide by federal packaging and labeling rules and they could not prevent companies from transporting hemp cannabinoids through their state regardless of their individual laws. As part of the labeling requirement proposed under the measure, all products would need to feature an internationally recognized symbol and statement identifying them as containing cannabinoids. States could use different symbols for intoxicating vs. non-intoxicating items. FDA would be required to promulgate rules on the remote sale, marketing and distribution of hemp cannabinoids to prevent youth use within 18 months of the measure’s enactment. Within nine months, the agency would need to establish good manufacturing processes for such products. In general, FDA would have the authority to enact additional regulations on the sale and production of hemp cannabinoids if they serve public health interests. Hemp cannabinoids could be considered as, or included in, food items if they meet Federal Food, Drug, and Cosmetic (FFD&C) Act standards laid out in the bill. However, businesses couldn’t sell cannabinoid products if they contain alcohol, tobacco or nicotine. Vapes containing cannabinoids could not have natural or artificial flavors, and they could contain no more than 6 percent terpenes. The bill states that synthetically derived cannabinoids would be banned, which is consistent with existing law but has generally gone without federal enforcement. For example, delta-8 THC products are commonly synthesized from legal CBD—something the Drug Enforcement Administration (DEA) has said violates statute—but those products are still widely available in loosely regulated state markets. Wyden’s measure also adds a definition for what constitutes total THC content, a measurement that determines whether a product is considered federally legal hemp or illegal marijuana. The Farm Bill defines hemp as cannabis containing up to 0.3 percent THC by dry weight, and that’s conventionally been understood to refer to the most commonly known intoxicating cannabinoid delta-9 THC. The new legislation stipulates that THC refers to the total content of the cannabinoid in all forms, including delta-8, delta-9, delta-10, THC-A and HHC, for example. Additionally, the heads of the U.S. Department of Agriculture (USDA), FDA, Justice Department and Alcohol and Tobacco Tax and Trade Bureau (TTB) would be required to work together to create a report with recommendations on regulating the sale of beverages containing THC. The legislation also provides for mandatory recalls of any hemp cannabinoid products that FDA determines to be unsafe. On top of the regulatory provisions, the Cannabinoid Safety and Regulation Act further calls for a series of agency directives and appropriations and grant initiatives to support relevant public health objectives. That includes $200 million in annual appropriations over five years for the Centers for Disease Control and Prevention (CDC) to support data collection on cannabis use trends and evidence-based prevention programs, mandatory data collection on impaired driving and $40 million in grants over five years for state agencies to combat driving under the influence and $30 million for research development to create a device capable of detected impaired driving. The bill is largely identical to a prior version of the hemp legislation filed last Congress, with select changes. Arguably the most notable revision is the imposition of THC limits for hemp products, which represents a departure from the earlier iteration of the proposal and seems to serve as a compromise agains the broad ban that is set to take effect next November under the newly enacted appropriations legislation. Under the new measure, testing facilities would need to be approved at the state level and registered with either DEA, FDA or USDA. The previous bill stipulated that testing facilities could have either state or federal approval. The earlier version of the measure also sought to create a new Center for Cannabinoid Products at FDA, which was removed from the current legislation. “We are deeply grateful to Senators Wyden and Merkley for their continued leadership on behalf of hemp farmers, consumers and businesses,” Jonathan Miller, general counsel at the U.S. Hemp Roundtable, told Marijuana Moment on Wednesday. “Introduction of their bill is a key first step to developing consensus around a robust regulatory framework that can replace the impending ban,” he said. “We are hopeful that Congress will extend the ban moratorium for at least another year to provide adequate time to consider, improve upon and resolve efforts such as Wyden/Merkley.” Dawson Hobbs, executive vice president of government affairs for the Wine and Spirits Wholesalers of America, said in a press release from Wyden’s office that the bill “would take steps to establish an effective framework to regulate the hemp market by requiring products to be tested and properly labeled and outlawing synthetic derived products.” “This legislation would allow states to continue implementing their own standards while setting important baseline public safety standards and ensuring that these products are not readily available to children,” he said. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the Congressional Research Service (CRS) recently released a report describing the significant uncertainty around how the pending federal hemp ban will ultimately be enforced, but “divergent federal and state marijuana laws may provide some guidance,” Hemp was federally legalized under the 2018 Farm Bill that Trump signed during his first term, with then-Senate Majority Leader Mitch McConnell (R-KY) leading the push to end criminalization of the crop at the time. But the senator has insisted that the policy change wasn’t intended to allow consumable products with THC, so he’s been determined to close what he describes as a “loophole” in the law. Sen. Rand Paul (R-KY) attempted to remove the hemp ban language from the spending bill Trump signed last month, but a majority of members voted to table his amendment. Industry stakeholders, advocates and lawmakers are stressing the urgency of the situation. While the hemp ban won’t take effect until one year after enactment, that still leaves little time in the congressional calendar to reverse course or create an alternative regulatory framework for products set to be banned. Paul, meanwhile, said last month that he’ll soon file a bill to protect the hemp industry from the impending hemp ban. And he also called out alcohol and marijuana interests for allegedly “join[ing] forces” to lobby in favor of the prohibitionist policy change, which will restrict access to a plant and its derivatives that are often used therapeutically. The senator said the forthcoming legislation would make it so state policy regulating hemp cannabinoid products—with basic safeguards in place to prevent youth access, for example—”supersedes the federal law.” On the other end of the debate, Rep. Andy Harris (R-MD), who helped secure the hemp re-criminalization language, said last month that he’s not concerned about attempts to undercut the enacted law, brushing off arguments about the possible consequences of the policy change as “desperate mistruths from an industry that stands to lose billions of dollars by selling intoxicants to children.” Overall, there’s been widespread outcry over the pending hemp re-criminalization law, drawing criticism from parents of cannabis patients, veterinarians and influencers like Joe Rogan, for example. In response to the hemp ban, Rep. Nancy Mace (R-SC) filed a bill that would strike the contested provisions of the appropriations legislation. But some stakeholders worry that approach could backfire, and they’re hoping to see bipartisan bills introduced in he near future that would provide a robust regulatory model for intoxicating hemp products as a viable alternative to blanket prohibition. Meanwhile, GOP political operative Roger Stone said last month that Trump was effectively “forced” by Republican lawmakers to sign the spending bill with the hemp THC ban language. However, a White House spokesperson said prior to the bill signing that Trump specifically supported the prohibition language. The Democratic governor of Kentucky said last month that the hemp industry is an “important” part of the economy that deserves to be regulated at the state level—rather than federally prohibited, as Congress has moved to do. Also, a leading veterans organization is warning congressional leaders that the newly approved blanket ban on consumable hemp products could inadvertently “slam the door shut” on critical research. While many hemp stakeholders say the ban would effectively eradicate the industry–even applying to nonintoxicating CBD products that people use for medical reasons—there’s latent hope that they can strike a compromise deal with lawmakers before the prohibition is implemented this time next year. Lawmakers such as Sen. Chris Van Hollen (D-MD) also say that window could provide an opportunity to advance legislation to create an alternative regulatory model for consumable hemp products. Since 2018, cannabis products have been considered legal hemp if they contain less than 0.3 percent delta-9 THC on a dry weight basis. The new legislation specifies that, within one year of enactment, the weight will apply to total THC—including delta-8 and other isomers. It will also include “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).” The new definition of legal hemp will additionally ban “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or not capable of being naturally produced by it. Legal hemp products will be limited to a total of 0.4 milligrams per container of total THC or any other cannabinoids with similar effects. Within 90 days of the bill’s enactment, the Food and Drug Administration (FDA) and other agencies will need to publish list of “all cannabinoids known to FDA to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer reviewed literature,” “all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant” and “all other known cannabinoids with similar effects to, or marketed to have similar effects to, tetrahyrocannabinol class cannabinoids.” The language slightly differs from provisions included in legislation that had previously advanced out of the House and Senate Appropriations panels, which would have banned products containing any “quantifiable” amount of THC, to be determined by the HHS secretary and secretary of agriculture. Read the full text of the new Senate bill below: Photo courtesy of Brendan Cleak. The post Hemp Products Would Be Federally Regulated Instead Of Banned Under New Senate Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I merely imagined it usually is a perception to write could possibly help anybody ended up being experiencing difficulity looking into nevertheless We are somewhat doubtful only are permitted to placed labels along with details in below. clip in hair extensions

Marijuana breeders may be able to design new strains and speed up their growing cycles by utilizing artificial intelligence (AI), a new study suggests. Researchers found that by feeding genetic markers, growth measurements, environmental data and chemical assays into AI models, breeders could simulate thousands of potential crosses and stimulate “speed breeding” through machine learning before ever planting a seed. The authors argue this approach could cut traditional breeding cycles, which currently last between six to eight years, down to a fraction of that time, while also improving consistency—a perennial challenge that commercial cannabis growers grapple with. “Machine learning allows for iterative simulations of breeding outcomes…while ensuring chemical consistency,” the authors concluded. “AI-enabled cannabis breeding represents a paradigm shift in strain development, enabling precise control over cannabinoid and terpene profiles while reducing breeding cycle times and resource requirements.” The paper also highlights the role of metabolomics, an emerging field that catalogs the vast array of chemicals produced by living organisms. “AI systems correlate these datasets to predict how specific genetic combinations will influence chemical composition and growth traits, enabling precise selection of parental strains for crossbreeding,” they observed. Techniques like genomic selection, regression analysis and deep learning are already used in major agricultural crops. Applied to cannabis, these tools look for patterns linking genetic variants to chemical traits such as the proportion of THC or the presence of rare cannabinoids like CBG. One of the biggest challenges in cannabis cultivation is the complex interaction between genetics and environment. Light spectrum, humidity, nutrient availability and subtle temperature shifts can reshape a plant’s chemical output. The study, which has not yet been published in a journal but was posted on the science site ResearchGate, describes how AI systems can incorporate these variables to predict performance in different growing environments—a tool that could be particularly valuable as the industry expands into diverse climatic regions. Neural networks can track nonlinear interactions among dozens of genes that influence plant chemistry, in addition to incorporating environmental conditions. “These innovations promise accelerated strain development, improved chemical consistency, and enhanced adaptability to diverse growing environments,” the authors, who are affiliated with the University of Saskatchewan and Renaissance Bioscience, noted. Using instruments like gas chromatography mass spectrometers, researchers can employ AI to measure cannabinoids and terpenes across a plant’s life cycle. Combined with imaging tools that assess traits such as trichome density or stress responses, these data points give AI models the raw material to make increasingly accurate predictions. “This capability allows breeders to design strains not only for chemical profiles but also for resilience and adaptability in diverse growing environments,” the researchers wrote. Highlighting the importance of reproducibility, they noted that “the global cannabis industry demands high-quality, reproducible strains, creating the need for precision breeding technologies that reduce time-to-market while maximizing yield and potency.” The writers cautioned that, for all its advantages, AI-enabled cannabis breeding faces challenges, including data quality constraints that affect the accuracy of genotypic and phenotypic predictions. They also note complications surrounding complex polygenic traits, ethical considerations and regulatory barriers, observing that “legal restrictions on cannabis research may limit data access.” Recent research on cannabis genetics suggests that incentives in the legal marijuana market—such as the desire for plants to mature faster and produce more cannabinoids for extraction—may be leading to a decline in biodiversity of the plant worldwide, prompting a researcher from California State Polytechnic University Humboldt to describe the problem as “the bottlenecking of Cannabis genetics.” And in 2022, the California Department of Cannabis Control funded a $20 million study to, as officials wrote, “identify and preserve the history, value and diversity of California legacy cannabis cultivars and the rich experience of its legacy cultivation community, and enable, enhance and guide the understanding and application of cannabis genetics to the greater body of research and science-based public policy development.” Interest in cannabis genetics is not confined to state level governments. In 2018, a powerful U.S. Senate committee directed agriculture authorities to begin building up the nation’s stockpile of cannabis genetics, setting aside half a million dollars to support the work. The post Marijuana Breeders Can Use AI To Design New Strains, Study Demonstrates appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Your own songs is actually incredible. You've a few really gifted designers. We desire a person the very best associated with achievement. slot gacor

As he campaigned for the 2024 Democratic presidential nomination, Robert F. Kennedy, Jr.–the current head of the U.S. Department of Health and Human Services (HHS) under the Trump administration—still used psychedelics like DMT “for fun” and hid his drug use from his wife, according to a book from a journalist who allegedly had a romantic relationship with him. The tell-all book from Olivia Nuzzi, titled “American Canto,” has gained attention for a variety of revelations that she disclosed about the administration and her personal affair with the “Politician”—a term she used in lieu of naming the official widely believed to be Kennedy. The health official has repeatedly denied the affair, but details included in the book leave little room for interpretation about who Nuzzi was describing. That includes a detail about the politician’s long-term sobriety, which Kennedy has spoken about at length, and his openness to psychedelics as an alternative therapy option. “The Politician was hyper-interested in whether I did drugs or took pharmaceuticals or drank alcohol. He loved to discuss drugs, psychedelic trips, all manner of related mind-altered esoterica,” Nuzzi wrote. “He said he was sober now and told me stories about when he was still using, a period that had lasted for more than fifteen years.” Conceding that she liked “uppers” such as Adderall, Nuzzi said Kennedy responded that his children take the prescription stimulant as well, but he “can’t.” “He lived for a summer with John Phillips and Keith Richards above a pharmacy where they were all strung out on amphetamines, he said,” she wrote. “Phillips had purchased the pharmacy in a stroke of junkie entrepreneurial genius.” “I credited psilocybin with saving my life after my mother died. I had not intended to utilize the psychedelic compound for therapeutic reasons; it just happened that way, that the grief I had been running from approached while I was on a moderate dose and I found that in such a state I could sit with it,” Nuzzi said. “He told me one of his sons processed grief with the assistance of ayahuasca.” That anecdote about his son’s experience is consistent with Kennedy’s prior accounting of how he came to embrace psychedelics therapy while he was on the campaign trail in 2023. But Nuzzi’s book included a key detail that the health secretary has not publicly discussed regarding his own experience with the currently controlled substances that his agency plays a critical role in overseeing. “The Politician still did some psychedelics for fun, he said,” the book says. “He described how he waited until his wife was not home to go outside and smoke DMT, just as he waited until she was not home to call, or else he would call while locked in the bathroom. ‘Is that the one with the toad?’ l asked.” “He laughed. ‘No,’ he said. DMT, or N,N-dimethyltryptamine, considered among the most potent hallucinogenic drugs, sends users into the stratosphere of ego death and back to earth in fifteen minutes. Psychedelic toad venom was something else,” Nuzzi wrote. “The DMT was laced in cigarettes a friend had given him. ‘What’s it like?’ I asked. He thought for a moment and flashed a mischievous smile. With a shrug, he said, ‘It’s your classic psychedelic experience.'” Also in the book, Nuzzi said the unnamed politician felt that “all addicts were pathological liars,” which stood out to her because he was “rarely as judgmental as he was about other addicts.” “I did not think to apply his assessment to him or to our relationship. I did not think to apply it even when he referred to me as an intoxicant,” she said. Nuzzi also spoke about the issue on The Bulwark podcast last week, saying that “it was in the public interest” to reveal the politician’s drug use. “This person who says that he’s sober, right? He was telling me privately that, in fact, he was not sober, and he was hiding it not just from the public, but from his own wife, among other things,” she said. The host asked Nuzzi if Kennedy was doing drugs other than DMT, such as ketamine. “I had asked him about another drug I heard that he was doing and he had emphatically denied it,” she replied. “But I can’t say that I make much of his emphatic denial of anything.” .@Olivianuzzi: "[RFK Jr.] was telling me privately that, in fact, he was not sober and he was hiding it not just from the public, but from his own wife."@Timodc: "You mentioned DMT…Is he doing ketamine?" https://t.co/CsHEdKMZ2w pic.twitter.com/1W6qbK6c0M — The Bulwark (@BulwarkOnline) December 3, 2025 Marijuana Moment reached out to HHS for comment, but a representative did not respond by the time of publication. While it would likely create controversy if it was the case that Kennedy continues to use psychedelics either medically or recreationally while serving in Trump’s cabinet, given their status as Schedule I drugs under the Controlled Substances Act (CSA), the official hasn’t been shy about his interest in reforming federal laws and promoting their therapeutic use. As recently as last month, Kennedy, Vice President JD Vance, the Food and Drug Administration (FDA) commissioner and other Trump administration officials attended a “Make America Healthy Again” summit that featured a session dedicated to exploring psychedelic medicine. In June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” The secretary also said in April that he had a “wonderful experience” with LSD at 15 years old, which he took because he thought he’d be able to see dinosaurs, as portrayed in a comic book he was a fan of. Last October, Kennedy specifically criticized FDA under the prior administration over the agency’s “suppression of psychedelics” and a laundry list of other issues that he said amounted to a “war on public health” that would end under the Trump administration. The post RFK Hid Psychedelic Trips From His Wife, Journalist Who Allegedly Had Affair With Him Says In New Book appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Legislators must ensure the launch mechanics don’t inadvertently hand the keys back to the incumbents before independent operators can even get in the door.” By Max Jackson, Cannabis Wise Guys For years, the story of legal cannabis in America has been a rerun of the same bad movie: corporate lobbyists write the rules, “Big Weed” captures the market and independent farmers are regulated into bankruptcy. Last week, Virginia’s Joint Commission to Oversee the Transition of the Commonwealth into a Retail Cannabis Market decided to change the channel. In October, I warned the Joint Commission in testimony that Virginia faced a choice between two economic models: “Path A,” a limited-license market dominated by incumbent multi-state operators (MSOs), or “Path B,” a competitive market built on independent Virginia businesses. The proposed legislative changes represent a genuine attempt to prevent the monopolization that has plagued legal cannabis markets across the country. The Commission has embraced restorative justice, killed the regulatory barriers that created “cannabis deserts” in other states and built a framework for independent operators to compete. The question is whether the operational timeline will deliver on that promise—or undermine it. The $10 Million “Penalty” Is Actually A Discount The proposal requires incumbent pharmaceutical processors to pay a $10 million fee to enter the adult-use market. To the average Virginian, that sounds like a hefty price tag. But let’s be honest about the math—and the history. Virginia’s medical program launched in 2020 as a limited-license, vertically-integrated market. Five pharmaceutical processors—most of them multi-state operators—were awarded exclusive territories with mandatory vertical integration, a structure designed to favor deep-pocketed incumbents over independent operators. Between July and August 2025 alone, that protected medical market recorded nearly $30 million in sales across more than 256,000 transactions. In 2024, The Cannabist Company sold its Eastern Virginia medical operation to Verano Holdings for $90 million. Just last week, The Cannabist sold its Central Virginia operation to Curaleaf for $110 million. Two territories, $200 million in total value. In exchange for this one-time $10 million conversion fee, these companies are being granted licenses that are larger and more powerful than any other tier available to new entrants. They retain their vertical integration—growing, processing and selling their own product—while new businesses are forced to specialize. They already have completed facilities, trained staff, established supply chains and consumer brand recognition. Against proven territory valuations of $90-110 million and a medical market generating $15 million per month, a $10 million conversion fee is not a penalty; it’s a discount on market dominance. Killing The “Cannabis Desert” The most significant victory for public safety is the removal of the local referendum option. The failure of the opt-out model is well-documented. In New Jersey, nearly 70 percent of municipalities initially opted out of allowing cannabis businesses, creating vast “cannabis deserts.” This didn’t stop consumption; it simply handed those markets directly to illicit operators who don’t check IDs or test their products. By striking the opt-out provision, the Commission has acknowledged a fundamental truth: you cannot regulate a market if you do not allow it to exist. However, access alone doesn’t guarantee competition. The proposal also establishes a one-mile minimum distance between retail dispensaries, intended to prevent the clustering seen in states like New Jersey, where zoning restrictions force retailers to open across the street from one another. In theory, this promotes geographic distribution. In practice, it transforms retail licensing into a real estate race—whoever secures a location first controls a one-mile radius, and well-capitalized operators with real estate teams will always move faster than independent applicants still assembling financing. Removing the opt-out provision helps by opening more geography to competition, but the mile-radius rule still advantages those who can play the property game at speed. Restorative Justice Requires Resources Equally important is the shift in how Virginia defines “impact.” The proposal to include prior felony distribution charges as a qualifier for impact status—rather than a disqualifier—is an absolute victory. It moves beyond performative equity and toward actual restorative justice, acknowledging that the expertise of legacy operators is a feature, not a bug. However, a license is only an opportunity if the resources exist to execute on it. The bill’s commitment to direct 50 percent of the Cannabis Equity Reinvestment Fund into loan capital is a start, but impact licenses are only as helpful as the funding, technical assistance and affordable professional services available to support them. Virginia must ensure these operators can access not just capital, but the legal, accounting and compliance expertise necessary to survive the capital-intensive startup phase—services that incumbents already have in-house. The 120-Day Trap As an operational consultant, I must be direct: the timeline in this proposal threatens to undo everything the policy structure is trying to achieve. Here’s the math. Assuming the bill passes early in 2026, the Cannabis Control Authority (CCA) has until July 1 to stand up regulations and process the first round of licenses. Retail sales begin November 1. That gives a newly licensed independent operator exactly 120 days to go from “license in hand” to “product on shelves.” Let me explain what 120 days actually means in cannabis cultivation. A typical flowering cycle runs 60-65 days. Add 3-4 weeks of vegetation before that. Then, 10-14 days for drying and curing. Then testing, packaging and compliance. You’re looking at 100-120 days minimum from clone to compliant, sellable product—assuming everything goes perfectly, your facility is already built, your systems are dialed in and you started cultivation the moment your license arrived. For a new operator still finishing construction, installing equipment, and training staff? The math doesn’t work. They will have nothing to sell on November 1. The pharmaceutical processors, meanwhile, already have inventory. They have flower curing in their vaults right now. They’ll be ready to sell on day one. Market Readiness, Not Calendar Dates The solution is straightforward: tie market launch to actual competitive readiness, not arbitrary dates. Virginia should establish “Market Readiness” benchmarks where retail sales begin when a minimum threshold of independent licensees—impact operators, microbusinesses and small cultivators—have received licenses, completed buildout and have product ready for sale. When the independents and the incumbents cross the starting line together, consumers get competition, prices reflect a real market and the policy achieves its stated purpose. This isn’t about delaying the market indefinitely. It’s about aligning the incentives of all market participants so that pharmaceutical processors, independent operators and the state all benefit from a stable, competitive launch. One approach would be to make pharmaceutical processor conversion contingent on independent operator readiness—perhaps even on a regional basis—so that cooperation becomes more profitable than obstruction. When incumbents’ adult-use revenue depends on independents getting operational, the market dynamics shift dramatically. The ready-together framework prevents the first-mover revenue trap that has cemented MSO dominance in state after state. Arizona launched sales roughly 80 days after licensing—but only incumbents with existing inventory could participate, giving them a 6-12 month head start that new operators never recovered from. Virginia has built the right policy framework to avoid that outcome. Now it must build the right launch mechanics. The Commission should amend the current timeline provisions to establish clear market readiness criteria: retail sales commence when the Cannabis Control Authority certifies that licensed independent operators have compliant product available for distribution, ensuring market launch reflects genuine competition rather than incumbent inventory advantage. This preserves the urgency of launching a regulated market while ensuring the Commission’s equity and competition goals aren’t undermined by a calendar date that only pharmaceutical processors can meet. “Operational” Must Mean Progress, Not Perfection The proposal includes a 24-month “use it or lose it” rule to prevent license speculation. That’s good policy—if “operational” is defined correctly. In Virginia’s current construction environment, the electrical transformers required for a commercial cannabis facility can face lead times of 12-18 months. Add permitting delays, zoning appeals and on-site construction, and the 24-month window becomes dangerously tight. The standard for retaining a license must be “demonstrable progress”—breaking ground, passing inspections, installing equipment, securing financing—not “open for business.” Without this clarity, the 24-month rule becomes another tool that advantages incumbents with completed facilities while punishing independents for delays entirely outside their control. Shell Company Scrutiny Needs Speed Limits The proposal includes provisions requiring the Cannabis Control Authority to scrutinize ownership agreements, management contracts and financing arrangements to prevent MSOs from using shell companies to control nominally “independent” licensees. This is vital—without it, every anti-consolidation provision in the bill becomes meaningless. However, regulatory scrutiny without statutory time limits can be as dangerous as no scrutiny at all. If CCA takes six months to review a management agreement or a financing deal, that delay alone can kill a small business burning through cash while waiting for approval. Virginia must establish clear timelines—30 to 60 days for standard reviews, with defined criteria for what triggers extended review—so that legitimate operators aren’t inadvertently strangled by bureaucratic pace. Virginia Can Lead—If It Finishes The Blueprint Virginia has rejected the monopoly model that has failed consumers and small businesses in state after state. The Commission has embraced restorative justice by making felony distribution convictions a qualifier, not a disqualifier. It has eliminated the local opt-out provisions that created “cannabis deserts” in New Jersey and elsewhere. It has built a framework for microbusinesses, shared processing hubs, and impact licensees to compete on a level playing field. But a blueprint is not a building. By establishing clear market readiness criteria that tie launch to competitive preparedness, defining “operational readiness” to protect legitimate businesses from bureaucratic delays and establishing time limits for regulatory review, Virginia can deliver on the promise of a truly competitive market. The Commonwealth has drawn the blueprint for what legal cannabis could look like. Now legislators must ensure the launch mechanics don’t inadvertently hand the keys back to the incumbents before independent operators can even get in the door. Max Jackson is the founder of Cannabis Wise Guys and specializes in translating between cannabis operations, investment, and public policy. He has provided expert testimony to the Virginia Legislature on preventing market consolidation in emerging cannabis markets. Photo courtesy of Max Jackson. The post Virginia Rejected A Monopoly Model For Marijuana, But Lawmakers Need To Finish The Job (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I merely imagined it usually is a perception to write could possibly help anybody ended up being experiencing difficulity looking into nevertheless We are somewhat doubtful only are permitted to placed labels along with details in below. flowers delivery in abu dhabi

There’s significant uncertainty around how a pending federal hemp ban will ultimately be enforced, but “divergent federal and state marijuana laws may provide some guidance,” according to congressional researchers. With the recriminalization of most consumable hemp products set to take effect next November after President Donald Trump signed a spending bill containing the cannabis prohibition, the Congressional Research Service (CRS) has released a report outlining the policy’s potential impacts. And much of the analysis and considerations for lawmakers turn to existing marijuana policies. “In recent decades, a number of states have enacted laws relaxing state controls on marijuana and regulating the use of the substance for medical or recreational purposes,” it says. “Marijuana remains a Schedule I controlled substance subject to stringent controls under federal law, and, notwithstanding changes to state laws, most activities involving medical and recreational marijuana violate” the Controlled Substances Act (CSA). “There are two key reasons why the U.S. Department of Justice (DOJ) does not comprehensively enforce the CSA with respect to marijuana,” the report—which includes a comprehensive analysis of the legislative history around hemp, a version of the cannabis crop that was federally legalized under the first Trump administration—says. As was detailed in a separate recent CRS report, DOJ “lacks the resources to prosecute all violations of the CSA and generally has not prioritized enforcement against small-scale violations or activities that comply with state law,” the researchers said in the new document. “It remains to be seen to what extent DOJ will prioritize CSA enforcement against products containing psychoactive cannabinoids other than delta-9 THC.” “If Congress wishes to affect DOJ enforcement priorities, it has the legal authority to increase or decrease funding or dictate how the agency may use appropriated funds,” the report says. Another reason that for the limited enforcement action against state marijuana laws is the fact that, since 2014, Congress has approved annual appropriations legislation with a rider preventing the Justice Department from using its funds to interfere in states’ medical cannabis programs. While those same protections don’t apply to recreational marijuana laws, CRS said that, in theory, if states were to reclassify consumable THC products that no long longer meet the federal definition of legal hemp as medical cannabis products instead, “the appropriations rider would apply to those products to the extent they are used for medical purposes in compliance with state law.” “If Congress wanted to alter the scope of the appropriations rider, including modifying how it applies to hemp-derived cannabinoid products, it could do so by legislation,” it says. “Another consideration for Congress is that, to the extent hemp-derived cannabinoid products are classified as marijuana, any change to CSA regulation of marijuana would also apply to those products.” The report also takes into consideration the potential impact of a federal marijuana rescheduling proposal that was initiated under the Biden administration and is now pending action by Trump, who said in August that a decision on moving cannabis from Schedule I to Schedule III of the CSA would come within weeks. “As of the date of publication of this Legal Sidebar, DOJ has not taken final action on the rescheduling proposal,” it says. “Congress has broad authority to change the status of a controlled substance through legislation and could change the status of marijuana before or after DEA makes any final scheduling decision. Congress could choose to act with respect to marijuana generally or with respect to hemp-derived cannabinoid products in particular.” “Finally, the change to the federal definition of hemp may also affect state cannabis regulation,” the report continues. “Federal and state cannabis laws generally operate independently, and both may apply simultaneously if there is no positive conflict between the two.” “However, the 2018 farm bill contains a provision that expressly prohibits states from regulating ‘the transportation or shipment of hemp or hemp products … through the State.’ As discussed in a CRS report, there has been significant litigation over whether federal law preempts certain state hemp regulations. It remains to be seen whether and how narrowing the federal definition of hemp will affect that litigation. If Congress enacted legislation to change how hemp-derived cannabinoid products are regulated, that could also affect the pending litigation. If Congress wishes to preempt or not preempt certain state regulations of hemp, it also has the authority to amend the preemption provision.” Hemp was federally legalized under the 2018 Farm Bill that Trump signed during his first term, with then-Senate Majority Leader Mitch McConnell (R-KY) leading the push to end criminalization of the crop at the time. But the senator has insisted that the policy change wasn’t intended to allow consumable products with THC, so he’s been determined to close what he describes as a “loophole” in the law. Sen. Rand Paul (R-KY) attempted to remove the hemp ban language from the spending bill Trump signed last month, but a majority of members voted to table his amendment. Industry stakeholders, advocates and lawmakers are stressing the urgency of the situation. While the hemp ban won’t take effect until one year after enactment, that still leaves little time in the congressional calendar to reverse course or create an alternative regulatory framework for products set to be banned. Paul, meanwhile, said last month that he’ll soon file a bill to protect the hemp industry from the impending hemp ban. And he also called out alcohol and marijuana interests for allegedly “join[ing] forces” to lobby in favor of the prohibitionist policy change, which will restrict access to a plant and its derivatives that are often used therapeutically. The senator said the forthcoming legislation would make it so state policy regulating hemp cannabinoid products—with basic safeguards in place to prevent youth access, for example—”supersedes the federal law.” On the other end of the debate, Rep. Andy Harris (R-MD), who helped secure the hemp re-criminalization language, said last month that he’s not concerned about attempts to undercut the enacted law, brushing off arguments about the possible consequences of the policy change as “desperate mistruths from an industry that stands to lose billions of dollars by selling intoxicants to children.” Overall, there’s been widespread outcry over the pending hemp re-criminalization law, drawing criticism from parents of cannabis patients, veterinarians and influencers like Joe Rogan, for example. In response to the hemp ban, Rep. Nancy Mace (R-SC) filed a bill that would strike the contested provisions of the appropriations legislation. But some stakeholders worry that approach could backfire, and they’re hoping to see bipartisan bills introduced in he near future that would provide a robust regulatory model for intoxicating hemp products as a viable alternative to blanket prohibition. Meanwhile, GOP political operative Roger Stone said last month that Trump was effectively “forced” by Republican lawmakers to sign the spending bill with the hemp THC ban language. However, a White House spokesperson said prior to the bill signing that Trump specifically supported the prohibition language. The Democratic governor of Kentucky said last month that the hemp industry is an “important” part of the economy that deserves to be regulated at the state level—rather than federally prohibited, as Congress has moved to do. Also, a leading veterans organization is warning congressional leaders that the newly approved blanket ban on consumable hemp products could inadvertently “slam the door shut” on critical research. While many hemp stakeholders say the ban would effectively eradicate the industry–even applying to nonintoxicating CBD products that people use for medical reasons—there’s latent hope that they can strike a compromise deal with lawmakers before the prohibition is implemented this time next year. Lawmakers such as Sen. Chris Van Hollen (D-MD) also say that window could provide an opportunity to advance legislation to create an alternative regulatory model for consumable hemp products. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Since 2018, cannabis products have been considered legal hemp if they contain less than 0.3 percent delta-9 THC on a dry weight basis. The new legislation specifies that, within one year of enactment, the weight will apply to total THC—including delta-8 and other isomers. It will also include “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).” The new definition of legal hemp will additionally ban “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or not capable of being naturally produced by it. Legal hemp products will be limited to a total of 0.4 milligrams per container of total THC or any other cannabinoids with similar effects. Within 90 days of the bill’s enactment, the Food and Drug Administration (FDA) and other agencies will need to publish list of “all cannabinoids known to FDA to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer reviewed literature,” “all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant” and “all other known cannabinoids with similar effects to, or marketed to have similar effects to, tetrahyrocannabinol class cannabinoids.” The language slightly differs from provisions included in legislation that had previously advanced out of the House and Senate Appropriations panels, which would have banned products containing any “quantifiable” amount of THC, to be determined by the HHS secretary and secretary of agriculture. The post Ongoing Marijuana Conflict Between States And Feds Could Provide ‘Guidance’ On How New Hemp Ban Will Be Enforced, Congressional Report Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Attractive blog post, the nation's a truly nice web log that you have got these, compete the best get the job done, can be once again. private transfer Punta Cana airport to Hard Rock Hotel

Frequent goes to here i will discuss the obvious way to appreciate it on your attempt, which often is why Now i am viewing the internet site day-to-day, in search of completely new, useful facts. Quite a few, many thanks! taruhan slot Certainly great, remarkable, fact-filled tips these. Ones own content articles Be required to fail, thinking that obviously is true these on top of that. One normally generate an intriguing browse. On earth do you enlighten So i'm shocked?: )#) Compete the great articles and reviews. JNETOTO I had most recently initiated a fabulous web page, the details you will provide you with here comes with really helped others really. Regards just for all of the effort & succeed. slot Helpful — I valued the transparency on player complaint resolution timelines. Quick, fair resolution processes prevent toxic situations from escalating. Real votes showed which teams are responsive. bandar togel Excellent roundup — I appreciated the filter for low-population but active servers. Smaller communities often offer friendlier vibes and cooperation. Real player rankings showed which small servers thrive. oma cuan Excellent list — the server comparison tools simplified my decision. Side-by-side stats like drop rates and population were priceless. Real votes added the final confirmation. situs slot Certainly great, remarkable, fact-filled tips these. Ones own content articles Be required to fail, thinking that obviously is true these on top of that. One normally generate an intriguing browse. On earth do you enlighten So i'm shocked?: )#) Compete the great articles and reviews. slot online Frequent goes to here i will discuss the obvious way to appreciate it on your attempt, which often is why Now i am viewing the internet site day-to-day, in search of completely new, useful facts. Quite a few, many thanks! slot gacor

Great job for publishing such a beneficial web site. Your web log isn’t only useful but it is additionally really creative too. situs slot

Comment supprimer votre compte ? Si vous avez décidé de suspendre votre compte, vous pouvez contacter le service client. Bien que nous ne sachions pas si cela est possible par téléphone, vous pouvez en revanche ouvrir une fenêtre de chat en direct ou envoyer un e-mail à BK code promo MelBet bénin I have read all the comments and suggestions posted by the visitors for this article are very fine,We will wait for your next article so only.Thanks! code promo 1xbet gratuit gn One of the exceptional advantages of this platform is receiving a promo code after creating an account. The MelBet promo code is beneficial for users because it increases their winnings on the MelBet World Free Bet site. If you haven't yet created your account, here are the different ways to do so melbet promo code 2026

It's which means that amazing together with inspiring. We really enjoy any designs together with whoever should get it all during the post shall be grinning. private van from Punta Cana airport to Hard Rock

It is and so wonderful in addition to resourceful. I just now appreciate this colorings in addition to the person who obtains the item from the send will likely be happy. private SUV transfer Punta Cana to Hard Rock Hotel

PA lawmakers on legalization chances; ME recriminalization initiative; TX hemp rules; OR marijuana labor lawsuit; VA consumer workplace protections Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Ohio lawmakers sent Gov. Mike DeWine (R) a bill to scale back the voter-approved marijuana legalization law by recriminalizing some cannabis activity and removing anti-discrimination protections for consumers while also also enacting new restrictions on hemp products The chairs of the Pennsylvania House and Senate Appropriations Committees discussed the prospects for legalizing marijuana—with the Republican chair of the Senate panel saying cannabis’s ongoing federal Schedule I status is one reason the state shouldn’t act yet. The Maine secretary of state’s office cleared anti-marijuana activists to begin collecting signatures for a ballot initiative to recriminalize recreational sales and home cultivation while instituting new product testing requirements for medical cannabis. The Texas Alcoholic Beverage Commission filed proposed rules banning the sale of consumable hemp products to people under the age of 21—with new scaled-back penalties from an earlier version allowing the suspension of licenses, rather than their outright cancellation, for initial violations. Oregon cannabis businesses are asking the U.S. Court of Appeals for the Ninth Circuit to uphold a judge’s ruling blocking a voter-approved law to require marijuana companies to enter into labor peace agreements with workers. The Virginia Department of Labor and Industry published guidance on marijuana consumers’ workplace protection rights under a recently enacted state law—noting that “cannabinoids may help treat the symptoms of cancer or the side effects of cancer treatment.” Since Minnesota legalized marijuana, thousands of people have been prosecuted for transporting small amounts of cannabis in their cars without storing it in the trunk or keeping it sealed in an original, labeled packaging from a dispensary. / FEDERAL Rep. Chris Deluzio (D-PA) tweeted, “Freedom and prosperity are what this country is all about. This amendment to the federal budget bill banning hemp would hurt consumer freedom and kill jobs in Western Pennsylvania—I’m opposed.” / STATES The New Jersey Senate Budget Committee approved a bill to crack down on unlicensed marijuana sales and restructure the Cannabis Regulatory Commission. The Ohio legislature’s Ibogaine Treatment Study Committee will meet on Wednesday. New York’s acting top marijuana regulator resigned at the request of Gov. Kathy Hochul (D) following the withdrawal of an administration case against a cannabis company. A Kentucky Department of Corrections parole officer forced a man to quit his job at a hemp company due to potential exposure to THC. Vermont regulators sent guidance about marijuana business third-party advertising offers. California regulators sent updates on various cannabis issues. Minnesota regulators will host a webinar about a grants program that invests communities disproportionately affected by cannabis prohibition on Friday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Boston, Massachusetts Cannabis Board will meet on Wednesday. / INTERNATIONAL Ontario, Canada launched a new effort to combat underage marijuana and alcohol sales. The Fiji Court of Appeal quashed a marijuana cultivation conviction. / SCIENCE & HEALTH A study indicated that “chronic CBD supplementation leads to [blood pressure] reduction.” A review concluded that “CBD shows promising antimicrobial properties against a range of oral bacteria and fungi, suggesting its potential application in managing oral health conditions.” A study found that “psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice.” / BUSINESS Stiiizy acquired 12 retail stores from Gold Flora. Cronos Group Inc. is acquiring CanAdelaar B.V. Trulieve Cannabis Corp. received commitments for a private placement of senior secured notes due 2030 for aggregate gross proceeds of $100 million. Cannabix Technologies Inc. passed Federal Communications Commission testing for its cannabis breath testing device. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Ohio bill to roll back cannabis legalization passes (Newsletter: December 10, 2025) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Many thanks for that publish as well as excellent ideas.. actually We additionally believe that effort is actually the most crucial ingredient of obtaining achievement. flower delivery abu dhabi

I find this forum very helpful, especially for those working in product development speed stars game. There may be no complaints about nitrile gloves at the moment, but that doesn't mean they can't be improved further using the suggestions shared here.